 |
上海和香港2021年6月2日 /美通社/ -- 致力于研發(fā)和商業(yè)化創(chuàng)新腫瘤療法的領(lǐng)先生物制藥公司--德琪醫(yī)藥有限公司（簡稱“德琪醫(yī)藥”，香港聯(lián)交所股票代碼：6996.HK）今日宣布，同類首款選擇性核輸出抑制劑——塞利尼索（selinexor）12項(xiàng)研究及成果入選歐洲血液學(xué)協(xié)會（EHA）年會。此屆 EHA 會議將于6月9日至6月17日在線上召開。
線上摘要
Phase 2 MARCH study of oral ATG-010 plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously exposed to an immunomodulatory agent and a proteasome inhibitor.
摘要編號：PB1670
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
摘要編號：S188
Selinexor containing regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies.
摘要編號：EP1002
Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed/refractory multiple myeloma (MM).
摘要編號：EP1008
Ciltacabtagene Autoleucel versus selinexor + dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) treated with ≥ 3 lines of prior therapy：A matching adjusted indirect comparison.
摘要編號：EP1049
Cost effectiveness comparison of belantamab mafodotin and selinexor in relapsed refractory multiple myeloma.
摘要編號：EP1173
Lymphocyte count effect on efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma（DLBCL）：A post-hoc analysis from phase 2B SADAL study.
摘要編號：EP530
Genomic correlates of respones to selinexor in multiple myeloma from the BOSTON study reveal a predictive signature.
摘要編號：EP936
Effects of selinexor on previously treated multiple myeloma (MM) with RAS-mutations.
摘要編號：EP966
Efficacy and safety of selinexor, bortezomib, and dexamethasone based on refractory status to lenalidomide in patients with previously treated multiple myeloma：A post-hoc analysis of the BOSTON study.
摘要編號：EP974
Survival among older patients with previously treated multiple myeloma treated with selinexor，bortezomib, and dexamethasone (XVd) in the BOSTON study.
摘要編號：EP976
Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.
摘要編號：EP924
關(guān)于德琪醫(yī)藥
德琪醫(yī)藥有限公司（簡稱“德琪醫(yī)藥”，香港聯(lián)交所股票代碼：6996.HK）是一家以研發(fā)為驅(qū)動的生物制藥領(lǐng)先企業(yè)，致力于為亞太乃至全球患者提供最領(lǐng)先的療法，治療腫瘤及其他危及生命的疾病。自2017年正式運(yùn)營以來，德琪醫(yī)藥通過合作引進(jìn)和自主研發(fā)，建立了一條從臨床前到臨床階段不斷延展的豐富產(chǎn)品管線。目前，德琪醫(yī)藥已在多個(gè)亞太市場獲得15個(gè)臨床批件（IND），并遞交了5個(gè)新藥上市申請（NDA）。德琪醫(yī)藥將以“醫(yī)者無疆，創(chuàng)新永續(xù)”為愿景，專注于同類首款和同類最優(yōu)療法的早期研發(fā)、臨床研究、藥物生產(chǎn)及商業(yè)化，解決亟待滿足的臨床需求。
